NMRD - Nemaura Medical Inc.
| Previous Close | 4.4900 |
| Open | 4.4400 |
| Bid | 3.6600 x 1200 |
| Ask | 6.0000 x 1300 |
| Day's Range | 4.1217 - 4.4400 |
| 52 Week Range | 3.8300 - 19.3000 |
| Volume | 8,274 |
| Avg. Volume | 10,034 |
| Market Cap | 91M |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2380 |
| Earnings Date | Feb 10, 2020 - Feb 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.50 |
- GlobeNewswire
Nemaura Medical announces expansion of SugarBEAT® offering with BEAT® Diabetes digital subscription services
Loughborough, England, Dec. 05, 2019 -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a.
- GlobeNewswire
Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors
The reverse split is expected to take effect at the market open on December 5, 2019. In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. Any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share of common stock.
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- GlobeNewswire
Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019
Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019. Dr. Faz Chowdhury, CEO of Nemaura commented, “This has been an exciting period for Nemaura as we officially commenced the commercial rollout plans for SugarBEAT® following our recent CE approval. As the world’s first non-invasive, safe, needle-free CGM, SugarBEAT® is uniquely positioned to target the underserved $80 billion market for Type 2 diabetics and pre-diabetics.
- GlobeNewswire
Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona
Loughborough, England, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona. Dr. Faz Chowdhury, Chief Executive Officer, discussed key milestones in the development and plans for the commercial rollout program for SugarBEAT® in the UK, Ireland, Germany and other key European markets following its recent CE mark approval in the European Union.
- Simply Wall St.
Is Nemaura Medical (NASDAQ:NMRD) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019
Loughborough, England , Sept. 12, 2019 -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on.
- GlobeNewswire
Nemaura Medical Reports Quarterly Results for First Quarter Ended June 30, 2019
Loughborough, England, Aug. 09, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the first quarter ended June 30, 2019. The credit facility is at 8% interest, with interest payments due quarterly and principal due in full at maturity in five years. The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. With adequate cash on hand and the credit facility, along with anticipated revenue, Management has instructed Maxim to suspend all ATM activities.
- GlobeNewswire
Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch
Loughborough, England, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced the first shipments of SugarBEAT® to diabetic and pre-diabetic patients in the United Kingdom. Nemaura Medical will present data from its first users as part of several presentations planned at a symposium being held by the Company at the European Association for the Study of Diabetes (EASD) conference in Barcelona on September 19, 2019.
- GlobeNewswire
Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors
Loughborough, England, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced an $8 million (USD) senior credit facility from existing major shareholders, with the first $3.5 million available immediately, to help fund the Company’s European commercial launch plans. The non-dilutive credit facility will carry 8% interest with quarterly payments and the principal due only upon maturity in 5 years. The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. Dr. Faz Chowdhury, CEO of Nemaura, stated, “Nemaura is at an exciting inflection point, having recently received CE Mark approval for SugarBEAT®, the world’s first non-invasive, needle-free, continuous glucose monitor. We recently submitted a De Novo 510(k) medical device application to the U.S. Food and Drug Administration for SugarBEAT®.
- GlobeNewswire
Nemaura Medical Inc. Appoints Chris Avery as Vice President of Global Business Operations to Support Global Commercial Launch of SugarBEAT®
Loughborough, England , July 18, 2019 -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive,.
- GlobeNewswire
Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration
Loughborough, England , July 10, 2019 -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive,.
- GlobeNewswire
Nemaura Provides Fiscal 2019 Year-End Business Update
Nemaura Medical, Inc. (NMRD), a medical technology company commercializing SugarBEAT®, a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided a business update for the fiscal year ending March 31, 2019 and reported on recent corporate developments.
- GlobeNewswire
Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report
Loughborough, England, June 14, 2019 -- – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive,.
- GlobeNewswire
Nemaura Announces CE Mark Approval of SugarBEAT®
Loughborough,England, May 29, 2019 -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable.
- Simply Wall St.
The Nemaura Medical (NASDAQ:NMRD) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold
Nemaura Medical Inc. (NASDAQ:NMRD) shareholders should be happy to see the share price up 14% in the last week. But...
- GlobeNewswire
Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels.
- GlobeNewswire
Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®
Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,’ in preparation for submission of its medical device application to the FDA for SugarBEAT®.
- GlobeNewswire
Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®
Loughborough, England , April 16, 2019 -- April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as.
- GlobeNewswire
Nemaura CEO Provides Update to Shareholders
Loughborough, England, March 28, 2019 -- Loughborough, England – March 28, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the.
- GlobeNewswire
Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region
Loughborough, England – March 12, 2019 – Nemaura Medical, Inc. (NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has signed an exclusive license and supply agreement for SugarBEAT® with TPMENA in the Gulf Cooperation Council (GCC) Region, which includes Bahrain, Kuwait, Saudi Arabia, Oman and United Arab Emirates. TPMENA is a distributor of medical devices in the GCC Region, backed by Cigalah group.
- GlobeNewswire
Nemaura Reports Third Quarter 2018 Financial Results
Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive,.
- GlobeNewswire
Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development
February 11, 2019 – Nemaura Medical, Inc. (NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that Dr. Fred Schaebsdau, MD, PhD, MBA has joined Nemaura to lead strategy and business development. Dr. Schaebsdau will advance Nemaura’s commercial strategy for its planned launch of SugarBEAT® in Europe, and advise regarding its upcoming 510(k) submission to the United States Food and Drug Administration.
- GlobeNewswire
Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm
February 7, 2019 – Nemaura Medical Inc. (NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) for use by diabetics and pre-diabetics, today announced the grant of U.S. Patent 10,092,224, Cumulative Measurement of an Analyte. SugarBEAT® CGM utilizes a proprietary, daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.
- GlobeNewswire
Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor
Loughborough, England –Nemaura Medical, Inc. (NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has substantially advanced the use-case for SugarBEAT® to improve management of glucose levels by spending more time in range. SugarBEAT® CGM utilizes a proprietary daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day. Nemaura has previously achieved industry-leading, skin-patch warm-up periods of less than one hour meaning that reliable glucose readings can be expected one hour after application of the skin-patch.
